2017 年第 2 期 第 15 卷

同期放疗联合内分泌治疗对中晚期前列腺癌患者生存质量的影响

作者：

单位：

关键词：同期放疗内分泌前列腺癌生存质量

• 摘要：
• 【摘要】【摘要】目的 探究同期放疗联合内分泌治疗对中晚期前列腺癌患者生存质量的影响。方法选取2011年9月-2013年2月在我院（黄陂区人民医院，湖北省肿瘤医院,咸宁中心医院，黄石市中心医院）接受治疗的中晚期前列腺癌患者82例，按照随机数表的方式随机分为对照组和实验组。对照组采用三维适形放射治疗方法，实验组在对照组的基础上增加内分泌治疗（口服比卡鲁胺50mg／次，1次／d，皮下注射戈舍瑞林3．6 mg,每28 d /1次）；两组患者生存质量的评测观察PSA（前列腺特异抗原）、最大尿流率、前列腺癌症状评分表（Expanded Prostate Cancer Index Composite，EPIC）各项数据得分以及两组患者在治疗后并发症数据。结果 实验组和对照组患者治疗后的最大尿流率数据分别为14.95±0.97ng/ml，11.03±0.98ml/s；实验组最大尿流率数据高于对照组（P<0.05）；实验组和对照患者EPIC泌尿功能得分分别为 88.9，81.7，实验组患者的评分高于对照组（P<0.05）；实验组和对照组患者在治疗期间并发症的总发生率分别为41.5%，70.7%，实验组患者的数据低于对照组数据（P<0.05）。结论 同期放疗联合内分泌治疗能够降低中晚期前列腺癌患者的血清PSA，改善患者生理功能状况，不良反应较少，且能够提高患者的生存质量，具有重要的临床推广价值。
• 【Abstract】 Objective To explore the same period radiotherapy combined with hormonal therapy for advanced prostate cancer patients quality of life impact. Methods 52 cases of patients of advanced prostate cancer were selected in our hospital（Huangpi District People's Hospital, Hubei Tumor Hospital, Xianning Central Hospital, Huangshi Central Hospital） from September 2011 to February 2013. 52 patients ,and divided into control group and experimental group according to a random number table.The control group with three-dimensional conformal radiation therapy were given, the experimental group increased in the control group based on endocrine therapywere given (oral bicalutamide 50mg / times, 1 times / d, subcutaneous goserelin 3.6 mg, every 28 d / 1); the quality of the two groups were observed survival reviews PSA (prostate specific antigen), maximum flow rate, EPIC data of the data points, and complicationsof patientsin two groups were observed after treatment .Results Experimental group and control group after treatment, the maximum urinary flow rate data were 14.95 + 0.97ng/ml, 11.03 + 0.98ml/s; experimental data data than the control group (P <0.05); experimental group and a control field EPIC urinary function scores were 88.9,81.7 patients, the experimental group were higher than the score; total experimental group and a control group of patients during treatment complications occurrence rates were 41.5%, 70.7%, side effects in the experimental group of patients, it is possible to improve the quality of life of patients (P <0.05).Conclusion Concurrent radiotherapy combined with Endocrinotherapy earlier can reduce serum PSA in patients with advanced prostate cancer, improve physiological function in these patients, fewer adverse reactions, and can improve the quality of life of patients, and has important clinical value.